Please login to the form below

Not currently logged in
Email:
Password:

Teva's asthma treatment Cinqaero set for European approval

CHMP backs the antibody therapy for eosinophilic asthma
Teva

Teva's asthma treatment Cinqaero (reslizumab)has been recommended for European approval by the Committee for Medicinal Products for Human Use (CHMP).

The antibody therapy was backed for use in combination with other medicines for the maintenance treatment of severe eosinophilic asthma in adults, who have had at least one asthma exacerbation in the year prior.

It is the second humanised interleukin-5 (IL-5) inhibitor to be recommended for approval in the EU, with GlaxoSmithKline's potential blockbuster Nucala (mepolizumab) already available on the market.

First licensed by the US FDA in March this year, Cinqaero showed in two clinical trials that it is able to reduce exacerbation rates by 50% and 60%, respectively, and improve lung function in patients.

However, analysts have suggested that GSK's subcutaneous formulation could give Nucala an edge over Cinqaero's intravenous injection.

Teva does have a subcutaneous version of its therapy in the works, but it is currently in phase III testing and so is unlikely to ready for filing for a few years.

Approximately 8% of people in the US have been diagnosed with asthma, and up to 20% of those are thought to suffer from severe asthma.

Article by
Rebecca Clifford

28th June 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics